Colloidal silicon dioxide in complex therapy of chronic opisthorchiasis

Abstract

BACKGROUND: The uniqueness of the natural data of the region of Western Siberia, the peculiarities of the hydrological regime ensure the stable functioning of foci of opisthorchiasis with a morbidity rate exceeding the indicators in Russia by more than 2 times. The long-term, sometimes forced coexistence of the human body and helminths often leads to serious consequences, which affects the general level of health of the population of endemic territories. With opisthorchiasis, allergies develop, functional disorders of organs (liver, kidneys) and systems (immune, cardiovascular, respiratory, endocrine, digestion), as well as disorders of fat, carbohydrate, mineral metabolism and, in general, hormonal background.

The diversity and non-specificity of the clinical manifestations of opisthorchiasis expands the relevance of this problem and requires an increase in the effectiveness of care for such patients, which necessitates the use of enterosorbents.

AIMS: is to analyze the effectiveness of the use of the enterosorbent silicon dioxide colloidal (Polysorb MP) in complex therapy of chronic opisthorchiasis.

MATERIALS AND METHODS: 214 patients with the chronic phase of opisthorchiasis were analyzed (57.5% of women and 42.5% of men aged 18 to 55 years). The diagnosis of opisthorchiasis invasion was confirmed when helminth eggs were found in the feces (in 72.7%), eggs and/or marites of opisthorchiasis in duodenal contents (in 27.3%). All patients received standard therapy, which included three stages: preparatory; specific chemotherapy; rehabilitation. The complex therapy of patients in the observation group at the stage of pathogenetic preparation included the use of colloidal silicon dioxide.

Statistical processing was carried out using methods of variational statistics.

RESULTS: The use of the drug silicon dioxide colloidal as part of the complex therapy of chronic opisthorchiasis contributes to a faster improvement ― the relief of allergic manifestations (when using silicon dioxide colloidal amounted to 2.41 (from 2 to 3) days and a significantly significant decrease in total cholesterol and atherogenicity index was noted.

CONCLUSION: Silicon dioxide colloidal has shown efficacy in the treatment of patients with opisthorchiasis invasion and disorders in lipid metabolism. Patients noted excellent tolerability and absence of side effects.

The method of enterosorption can be recommended for the treatment of opisthorchiasis invasion in patients with lipid metabolism disorders.

Keywords

opisthorchiases / lipid metabolism disorders / treatment / enterosorption / silicon dioxide colloidal

References

[1] On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2020: state report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; 2021. 256 p. (In Russ).

[2] О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2020 году: государственный доклад. Москва: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2021. 256 с.

[3] Yurlova NI, Yadrenkina EN, Rastyazhenko NM, et al. Opisthorchiasis in Western Siberia: epidemiology and distribution in human, fish, snail, and animal populations. Parasitol Int. 2017;66(4):355–364. doi: 10.1016/j.parint.2016.11.017

[4] Yurlova N.I., Yadrenkina E.N., Rastyazhenko N.M., et al. Opisthorchiasis in Western Siberia: epidemiology and distribution in human, fish, snail, and animal populations // Parasitol Int. 2017. Vol. 66, N 4. Р. 355–364. doi: 10.1016/j.parint.2016.11.017

[5] Verizhnikova LN, Aryamkina OL, Terentyeva NN. Somatic pathology in residents of Khanty-Mansi Autonomous Okrug ― Yugra. Bulletin of Siberian Medicine. 2020;19(2):13–19. (In Russ). doi: 10.20538/1682-0363-2020-2-13-19

[6] Верижникова Л.Н., Арямкина О.Л., Терентьева Н.Н. Соматическая патология у жителей Ханты-Мансийского автономного округа ― Югры // Бюллетень сибирской медицины. 2020. Т. 19, № 2. С. 13–19. doi: 10.20538/1682-0363-2020-2-13-19

[7] Golovach EA, Fedorova OS, Saprina TV, et al. Metabolic syndromes, carbohydrate and lipid metabolism disorders in helminthic infections: review of the literature. Bulletin of Siberian Medicine. 2018;17(4):187–198. (In Russ). doi: 10.20538/1682-0363-2018-4-187-198

[8] Головач Е.А., Федорова О.С., Саприна Т.В., и др. Метаболический синдром, нарушения углеводного и липидного обмена при гельминтозах: обзор современных данных // Бюллетень сибирской медицины. 2018. Т. 17, № 4. С. 187–198. doi: 10.20538/1682-0363-2018-4-187-198

[9] Degtyareva YuV, Vorob’eva EI, Karbysheva NV, et al. Changes in lipid metabolism in opisthorchiasis. Clinical Laboratory Diagnostics. 2007;(9):58–58a.

[10] Дегтярева Ю.В., Воробьева Е.И., Карбышева Н.В., и др. Изменение показателей липидного обмена при описторхозе // Клиническая лабораторная диагностика. 2007. № 9. С. 58–58a.

[11] Cukanov VV, Tonkih YuL, Gilyuk AV, et al. Opisthorchiasis: diagnostics, clinical manifestations, and management. Doctor.Ru. 2019;(8):49–53. (In Russ). doi: 10.31550/1727-2378-2019-163-8-49-53

[12] Цуканов В.В., Тонких Ю.Л., Гилюк А.В., и др. Диагностика, клиника и лечение описторхоза // Доктор.Ру. 2019. № 8. С. 49–53. doi: 10.31550/1727-2378-2019-163-8-49-53

[13] Cukanov VV, Gorchilova EG, Tonkih YuL, et al. Indicators of antioxidant status and oxidative stress in opisthorchiasis. Medical Council. 2021;(5):62–67. (In Russ). doi: 10.21518/2079-701X-2021-5-62-67

[14] Цуканов В.В., Горчилова Е.Г., Тонких Ю.Л., и др. Клинико-биохимическая характеристика больных с инвазией Opisthorchis felineus // Медицинский совет. 2021. № 5. С. 62–67. doi: 10.21518/2079-701X-2021-5-62-67

[15] Karbysheva NV, Bobrovskiy EA, Saldan IP, et al. Manifestation of liver pathology in chronic opisthorchiasis, issues of diagnosis and prevention. Epidemiology and Infectious Diseases. 2018;23(1):40–43.

[16] Карбышева Н.В., Бобровский Е.А., Салдан И.П., и др. Манифестация патологии печени при хроническом описторхозе, вопросы диагностики и профилактики // Эпидемиология и инфекционные болезни. 2018. Т. 23, № 1. С. 40–43.

[17] Tsukanov VV, Vasyutin AV, Tonkikh YuL, et al. Possibilities of using enterosorbent in combination therapy of patients with opisthorchiasis with skin syndrome. Medical Council. 2020;(5):70–76. doi: 10.21518/2079-701X-2020-5-70-76

[18] Цуканов В.В., Васютин А.В., Тонких Ю.Л., и др. Возможности применения энтеросорбента в комбинированной терапии больных описторхозом с кожным синдромом // Медицинский совет. 2020. № 5. С. 70–76. doi: 10.21518/2079-701X-2020-5-70-76

[19] Howell CA, Markaryan E, Allgar V, et al. Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial. BMJ Open Gastroenterol. 2019;6(1):e000287. doi: 10.1136/bmjgast-2019-000287

[20] Howell C.A., Markaryan E., Allgar V., et al. Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial // BMJ Open Gastroenterol. 2019. Vol. 6, N 1. Р. e000287. doi: 10.1136/bmjgast-2019-000287

[21] Menshikova SV, Ketova GG, Popilov MA. The use of enterosorbent Polysorb MP (colloidal silicon dioxide) in the complex therapy of various pathological conditions in children. Modern Problems of Science and Education. 2016;(6):184.

[22] Меньшикова С.В., Кетова Г.Г., Попилов М.А. Применение энтеросорбента Полисорб МП (кремния диоксида коллоидного) в комплексной терапии различных патологических состояний у детей // Современные проблемы науки и образования. 2016. № 6. С. 184.

RIGHTS & PERMISSIONS

Eco-vector